
Opinion|Videos|January 3, 2024
Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
Experts detail the management of ocular toxicity associated with tisotumab vedotin in patients with cervical cancer, emphasizing the need for eye care professionals and a team approach, along with addressing peripheral neuropathy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5




































